Morgan Stanley’s Labcorp LH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$451M Buy
1,609,447
+111,420
+7% +$29.3M 0.02% 620
2026
Q1
$400M Sell
1,498,027
-7,512
-0.5% -$2.03M 0.02% 619
2025
Q4
$378M Sell
1,505,539
-1,831
-0.1% -$486K 0.02% 634
2025
Q3
$433M Sell
1,507,370
-31,061
-2% -$8.32M 0.03% 576
2025
Q2
$404M Sell
1,538,431
-36,749
-2% -$8.95M 0.03% 576
2025
Q1
$367M Buy
1,575,180
+156,465
+11% +$38M 0.03% 582
2024
Q4
$325M Buy
1,418,715
+50,236
+4% +$11.5M 0.02% 629
2024
Q3
$306M Buy
1,368,479
+57,558
+4% +$12.7M 0.02% 636
2024
Q2
$267M Buy
1,310,921
+16,330
+1% +$3.32M 0.02% 667
2024
Q1
$283M Sell
1,294,591
-639,572
-33% -$141M 0.02% 649
2023
Q4
$440M Sell
1,934,163
-285,128
-13% -$59.9M 0.04% 446
2023
Q3
$446M Buy
2,219,291
+944,087
+74% +$199M 0.05% 394
2023
Q2
$264M Sell
1,275,204
-11,229
-0.9% -$2.18M 0.03% 608
2023
Q1
$254M Sell
1,286,433
-247,504
-16% -$50.9M 0.03% 611
2022
Q4
$310M Buy
1,533,937
+253,940
+20% +$49.6M 0.04% 502
2022
Q3
$225M Buy
1,279,997
+70,719
+6% +$14.5M 0.03% 530
2022
Q2
$243M Buy
1,209,278
+355,277
+42% +$75.7M 0.03% 515
2022
Q1
$193M Sell
854,001
-123,325
-13% -$29M 0.03% 543
2021
Q4
$264M Sell
977,326
-13,823
-1% -$3.42M 0.03% 467
2021
Q3
$240M Sell
991,149
-11,823
-1% -$2.98M 0.03% 465
2021
Q2
$238M Sell
1,002,972
-175,690
-15% -$40M 0.03% 486
2021
Q1
$258M Sell
1,178,662
-235,222
-17% -$47.2M 0.04% 407
2020
Q4
$247M Buy
1,413,884
+511,096
+57% +$88.3M 0.04% 405
2020
Q3
$146M Buy
902,788
+39,066
+5% +$6.19M 0.03% 471
2020
Q2
$123M Buy
863,722
+146,012
+20% +$20.2M 0.03% 479
2020
Q1
$77.9M Sell
717,710
-35,083
-5% -$5.05M 0.02% 566
2019
Q4
$109M Buy
752,793
+168,843
+29% +$24.4M 0.03% 572
2019
Q3
$84.3M Buy
583,950
+154,864
+36% +$22.6M 0.02% 621
2019
Q2
$63.7M Sell
429,086
-10,088
-2% -$1.41M 0.02% 731
2019
Q1
$57.7M Sell
439,174
-287,832
-40% -$35.5M 0.02% 768
2018
Q4
$78.9M Sell
727,006
-444,787
-38% -$59.6M 0.02% 618
2018
Q3
$175M Buy
1,171,793
+276,937
+31% +$42.1M 0.04% 391
2018
Q2
$138M Buy
894,856
+89,972
+11% +$13.6M 0.04% 455
2018
Q1
$112M Sell
804,884
-134,170
-14% -$19.7M 0.03% 536
2017
Q4
$129M Buy
939,054
+437,031
+87% +$57.8M 0.04% 492
2017
Q3
$65.1M Sell
502,023
-475,615
-49% -$63.4M 0.02% 762
2017
Q2
$129M Buy
977,638
+438,356
+81% +$53.7M 0.04% 461
2017
Q1
$66.5M Buy
539,282
+59,991
+13% +$7.1M 0.02% 759
2016
Q4
$52.9M Sell
479,291
-1,074
-0.2% -$119K 0.02% 836
2016
Q3
$56.7M Buy
480,365
+11,562
+2% +$1.36M 0.02% 777
2016
Q2
$52.5M Buy
468,803
+66,655
+17% +$7.17M 0.02% 769
2016
Q1
$40.5M Buy
402,148
+85,200
+27% +$8.17M 0.02% 880
2015
Q4
$33.7M Sell
316,948
-5,659
-2% -$584K 0.01% 1052
2015
Q3
$30.1M Buy
322,607
+59,943
+23% +$6.2M 0.01% 1093
2015
Q2
$27.4M Sell
262,664
-220,474
-46% -$22.9M 0.01% 1243
2015
Q1
$52.3M Buy
483,138
+155,670
+48% +$16M 0.02% 832
2014
Q4
$30.4M Buy
327,468
+529
+0.2% +$46.7K 0.01% 1164
2014
Q3
$28.6M Buy
326,939
+14,913
+5% +$1.35M 0.01% 1169
2014
Q2
$27.4M Buy
312,026
+32,496
+12% +$2.81M 0.01% 1179
2014
Q1
$23.6M Buy
279,530
+115,002
+70% +$9.17M 0.01% 1245
2013
Q4
$12.9M Buy
164,528
+47,790
+41% +$4.08M 0.01% 1719
2013
Q3
$9.94M Sell
116,738
-465
-0.4% -$39.2K ﹤0.01% 1776
2013
Q2
$10.1M Buy
+117,203
New +$9.73M 0.01% 1701

Other funds holding LH

Morgan Stanley's LH Position: Q2 2026 in Review

Morgan Stanley increased its Labcorp (LH) stake by 7.4% in Q2 2026, buying an estimated $29.3M and bringing the position to 1,609,447 shares worth $451M. The position accounts for 0.02% of the portfolio, ranked #620.

Morgan Stanley first reported a position in LH in Q2 2013 and has held it in 53 quarters since. 1,053 funds tracked by Wall St. Rank hold LH as of Q2 2026.

  • Morgan Stanley held 1,609,447 shares of Labcorp worth $451M as of Q2 2026.
  • Morgan Stanley bought 111,420 Labcorp shares in Q2 2026, an estimated $29.3M.
  • Labcorp made up 0.02% of Morgan Stanley's portfolio in Q2 2026, its #620 holding.
  • Morgan Stanley first reported a position in Labcorp in Q2 2013 and has held it in 53 quarters since.
  • 1,053 funds tracked by Wall St. Rank held Labcorp as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.